

Date: February 05, 2020

To,
The Chief Manager,
Surveillance
National Stock Exchange of India Ltd.,
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai-400 051.

Dear Sir,

Sub: Increase in volume.

With reference to your letter No. NSE/CM/Surveillance/9047 dated February 04, 2020 sent to us by mail yesterday, we wish to inform you that the unaudited financial results for the quarter / nine months ended 31 December 2019 were approved by our Board of Directors at their meeting held on Saturday, 1st February 2020. The said results were disclosed to both NSE and BSE within the specified time, on the same day, and also published in the newspapers yesterday, as required under SEBI (LODR) Regulations, 2015. We have also filed an Investor Presentation outlining the highlights of the performance.

Please note that apart from the above, there is no other price-sensitive information that may have a bearing on the operation/performance of the Company, which has not been disclosed to the Exchanges.

Thanking you,

Yours faithfully,

For Thyrocare Technologies Limited,



Ramjee Dorai
Company Secretary & Compliance Officer



Thyrocare Technologies Limited

📍 D-37/1, TTC MIDC, Turbhe, Navi Mumbai - 400 703, India ☎ 022- 3090 0000 / 4125 2525

✉ enquiry@thyrocare.com 🌐 www.thyrocare.com

(CIN : L85110MH2000PLC123882)